Entresto® is a newly approved combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker (ARB) for patients who have chronic heart failure NYHA Class II-IV and reduced ejection fraction.
Germin Fahim
Advertisement
Germin Fahim, Pharm.D., BCPS is Clinical Assistant Professor at Ernest Mario School of Pharmacy at Rutgers University, and Clinical Pharmacist at Monmouth Medical Center in Long Branch, New Jersey.
Articles by Germin Fahim
Advertisement
Latest Updated Articles
- New combo therapy for chronic heart failure
Published: December 15th 2016 | Updated:
Advertisement
Advertisement
Trending on Drug Topics
1
Most Favored Nation, Direct-to-Consumer Strategies Reshape US Pharma Landscape, Challenging Traditional Care
2
Wicked Good Cardiometabolic Chat: SGLT2is Offer Cardiorenal Benefits Beyond Diabetes
3
A1c Monitoring Could Be Delayed Up to 2 Years for Patients With Type 2 Diabetes
4
Q&A: The Initiative Bringing Clinical Pharmacy Care to Underserved Patients’ Homes
5
